

**Brandes Investment Partners**  
**U.S. Small Cap Value Equity Strategy Notes**  
**Fourth Quarter 2025 (1 October – 31 December 2025)**

The Brandes U.S. Small Cap Value Equity Strategy returned 6.16% (gross of fees), outperforming its benchmark, the Russell 2000 Index, which rose 2.19%, and the Russell 2000 Value Index, which gained 3.26%.

***Positive Contributors***

Leading contributors included holdings in the industrials sector, led by machinery companies Kennametal and Graham Corporation, as well as aerospace and defense businesses Moog and Hexcel.

Other strong performers included containers and packaging business Sealed Air, energy equipment and services business Innovex International, and Avadel Pharmaceuticals. In October, Avadel announced it would be acquired by Alkermes for a total value of \$2.1 billion with the full value subject to FDA approval of Lumryz for treating idiopathic hypersomnia in adults by the end of 2028. The following month, H. Lundbeck made an unsolicited proposal valuing Avadel at about \$2.4 billion, prompting Alkermes to raise its offer. Amid the bidding war, Avadel's share price reached our estimate of its intrinsic value, leading us to divest our position.

***Performance Detractors***

Health care was the best performing sector in the index, led by the biotechnology industry, and our underweight was a relative detractor. Further, select holdings in the sector declined, namely Utah Medical Products and Grifols.

Other detractors included Edgewell Personal Care, security systems company Arlo Technologies, communications equipment business Netgear and pizza restaurant chain Papa John's International. Netgear's decline was primarily due to concerns over supply chain issues, rising memory costs, and a mixed outlook from management during its third quarter earnings call. Meanwhile, Arlo was met with unease about its declining year-over-year free cash flow margin.

***Select Activity in the Quarter***

We bought Central Garden & Pet Company (CENT) while selling Pediatrix Medical Group and Avadel Pharmaceuticals.

Central Garden & Pet is a leading U.S. distributor and manufacturer in the lawn, garden, and pet supply industries. Founded in 1980, it initially focused on distributing lawn and garden products, later expanding through acquisitions to include pet supplies. During the past 30 years, CENT has completed 60 acquisitions and evolved into a market leader, manufacturing both branded and private label products for national retailers.

Slowing revenue growth from post-pandemic demand normalisation, increased competition from low-cost overseas suppliers and shifting consumer spending habits have weighed on CENT's share price, creating an attractive investment opportunity at current levels. Despite the top-line pressure, CENT has demonstrated resilience in maintaining its operating margins, supported by its ongoing Cost and Simplicity Program, which is midway through implementation. We believe further margin expansion and profitability improvements are possible, especially given the operational complexity introduced by decades of mergers and acquisitions-driven growth. Management is also shifting the company's product mix toward higher-margin consumable pet products and focusing on product innovation and further acquisitions to drive top-line growth. Additionally, we believe that the long-term prospects for the pet and garden industry are supported by durable trends.

***Year-to-Date Briefing***

The Brandes U.S. Small Cap Value Equity Strategy rose 24.69%, outperforming its benchmark, the Russell 2000 Index, which delivered 12.81% in 2025, and the Russell 2000 Value Index, which increased 12.59%.

Stock selection across multiple sectors drove our outperformance relative to the benchmark. Leading contributors included select holdings in health care and industrials, specifically Moog, Park Aerospace, machinery company Graham Corporation, Elanco Animal Health, Orion Group, and Avadel Pharmaceuticals. The strategy also benefited from solid returns delivered by Arlo Technologies and Innovex International.

Detractors were mainly in consumer staples and consumer discretionary sectors, namely Edgewell Personal Care and American Outdoor Brands, as well as juvenile products and home furnishings manufacturer Dorel Industries. Professional services company Resources Connection, machinery business Hurco Companies, and Utah Medical Products also declined.

### **Current Positioning**

Allocation to companies in industrials continues to be the largest weighting and overweight position from a sector standpoint. The portfolio also maintains key weights in health care, materials, and consumer discretionary. The strategy's most notable underweights are in financials, health care, information technology, and real estate. Compared to the Russell 2000 Value Index, we have significantly less exposure to financials and real estate.

In our opinion, the differences between the Brandes U.S. Small Cap Value Equity Strategy and the broader U.S. small-cap market continue to make it an attractive complement to other small-cap offerings. Our strategy exhibits lower valuations than the Russell 2000 Index, while offering exposure to companies that we believe have strong balance sheets, compelling growth prospects and a history of durable free-cash-flow generation.

We are optimistic about the potential of value stocks in general and believe the Brandes U.S. Small Cap Value Equity Strategy remains well positioned from a long-term risk/reward perspective.

For term definitions, please refer to <https://www.brandes.com/emea/termdefinitions>.

For index definitions, please refer to <https://www.brandes.com/emea/benchmark-definitions>.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. European and emerging markets investing are subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

**Ireland/Europe:** FOR PROFESSIONAL INVESTOR USE ONLY. Issued by Brandes Investment Partners (Europe) Limited (Brandes Europe), Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland. Registered in Ireland Number 510203. Authorised and regulated by the Central Bank of Ireland. This report is being provided for information purposes only, no representation or warranty is made, whether express or implied as to the accuracy or completeness of the information provided. To the fullest extent permitted by law Brandes Europe shall not be liable for any loss or damage suffered by any person as a result of the receipt of this report. Recipients of this report should obtain their own professional advice. The distribution of this report may be restricted by law. No action has been or will be taken by Brandes Europe to permit the possession or distribution of this report in any jurisdiction where action for that purpose may be required. Accordingly, this report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this report is communicated should inform themselves about and observe any such restrictions. This information is being issued only to, and/or is directed only at (i) persons who have professional experience in matters relating to investments or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This report is a confidential communication to, and solely for the use of, the persons to whom it is distributed to by Brandes Europe.